This resource is for educational purposes only. It does not constitute medical advice. We do not sell peptides or recommend products.

1. Overview

Carfilzomib is a second-generation, irreversible proteasome inhibitor belonging to the epoxyketone class of peptide-based anticancer agents. Marketed as Kyprolis by Amgen (originally Onyx Pharmaceuticals), it was granted accelerated FDA approval on July 20, 2012 for the treatment of patients with relapsed and refractory multiple myeloma (RRMM) who had received at least two prior therapies including bortezomib and an immunomodulatory agent [6]. Subsequent supplemental approvals in 2016 and 2018 expanded its indications to combination regimens in patients with one to three prior lines of therapy.

Carfilzomib's development traces back to the discovery of epoxomicin, a natural product epoxyketone isolated from an Actinomyces strain (Q996-17) in 1992, which was shown by Craig Crews' laboratory at Yale University to be a potent and selective proteasome inhibitor [1][2]. The Crews group subsequently developed a more potent and selective derivative, YU-101, which was licensed to Proteolix, Inc. Scientists at Proteolix addressed the poor aqueous solubility of YU-101 by appending a morpholine ring to the N-terminus, yielding carfilzomib (PR-171) with approximately 1,000-fold improved aqueous solubility [4][5]. Onyx Pharmaceuticals acquired Proteolix in 2009, and Amgen subsequently acquired Onyx in 2013 for $10.4 billion, driven largely by the commercial potential of Kyprolis.

Unlike the first-generation proteasome inhibitor bortezomib (Velcade), which utilizes a boronic acid warhead to form a slowly reversible tetrahedral adduct with the catalytic threonine, carfilzomib's epoxyketone pharmacophore forms two covalent bonds with the N-terminal threonine of the proteasome beta-5 subunit, creating an irreversible morpholino adduct [3]. This dual-covalent binding mechanism confers greater selectivity (eliminating off-target serine and cysteine protease inhibition), more sustained proteasome suppression, and a differentiated toxicity profile -- notably less peripheral neuropathy but more cardiovascular adverse events compared with bortezomib [10][11].

Type: Tetrapeptide epoxyketone proteasome inhibitor (epoxomicin derivative)
Molecular Weight: 719.91 Da
Molecular Formula: C40H57N5O7
Structure: Tetrapeptide with C-terminal alpha,beta-epoxyketone warhead and N-terminal morpholine
Origin: Synthetic analog of epoxomicin (from Actinomyces strain Q996-17)
CAS Number: 868540-17-4
Half-life: Less than 1 hour (rapid extrahepatic clearance)
Protein Binding: 97%
Metabolism: Peptidase cleavage and epoxide hydrolysis (non-CYP450)
Approved Doses: 20/27 mg/m2 (KRd); 20/56 mg/m2 (Kd twice-weekly); 20/70 mg/m2 (Kd once-weekly)
FDA Approval: July 20, 2012 (accelerated); January 2016 and January 2018 (supplemental)
Trade Name: Kyprolis (Onyx Pharmaceuticals/Amgen)

2. Molecular Structure and Properties

Carfilzomib belongs to the tetrapeptide epoxyketone class -- a structural family defined by a peptide backbone of four amino acid residues bearing an alpha,beta-epoxyketone electrophilic warhead at the C-terminus [4][5].

2.1 Chemical Identity

The molecule consists of four sequential amino acid residues -- morpholine-capped at the N-terminus and terminated by the epoxyketone warhead at the C-terminus:

N-terminal morpholine cap: Replaces the natural N-terminal group of the parent compound YU-101, dramatically improving aqueous solubility from approximately 1 microg/mL to approximately 1 mg/mL
Tetrapeptide backbone: Incorporates (S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylcarbamoyl residues with leucine, phenylalanine, and homophenylalanine moieties
C-terminal epoxyketone warhead: The alpha,beta-epoxyketone group is the pharmacophore responsible for irreversible proteasome inhibition; it reacts stereospecifically with the hydroxyl and amino groups of the catalytic Thr1 residue

2.2 Physicochemical Properties

| Property | Value | |----------|-------| | Molecular formula | C40H57N5O7 | | Molecular weight | 719.91 Da | | CAS number | 868540-17-4 | | Appearance | White to off-white lyophilized powder | | Solubility | Approximately 1 mg/mL in water; freely soluble in DMSO | | logP | Approximately 4.2 | | Number of chiral centers | 5 | | Epoxide configuration | (R)-configured alpha,beta-epoxyketone | | Structural class | Tetrapeptide epoxyketone |

2.3 Relationship to Epoxomicin

Carfilzomib is a synthetic analog of epoxomicin, the founding member of the epoxyketone proteasome inhibitor class [1][2][3]:

Epoxomicin was first isolated in 1992 from Actinomyces strain Q996-17 and characterized as a potent antitumor agent, though its molecular target was unknown at the time
In 1999, the Crews laboratory demonstrated that epoxomicin selectively inhibited the proteasome, specifically the chymotrypsin-like (beta-5) activity [2]
In 2000, the crystal structure of epoxomicin bound to the yeast 20S proteasome revealed the unprecedented dual-covalent mechanism involving morpholino ring formation with the catalytic threonine [3]
YU-101 was developed as a more potent derivative with optimized peptide backbone for beta-5 selectivity
Carfilzomib (PR-171) was derived from YU-101 by addition of the N-terminal morpholine solubilizing group, enabling clinical development [4]

3. Mechanism of Action

3.1 Irreversible Proteasome Inhibition via Dual Covalent Bond Formation

The defining mechanistic feature of carfilzomib is its irreversible, stereospecific inhibition of the chymotrypsin-like (beta-5) subunit of the 20S proteasome [3][5]:

Substrate recognition: The tetrapeptide backbone of carfilzomib binds within the substrate-binding channel of the beta-5 subunit, positioning the epoxyketone warhead adjacent to the catalytic N-terminal threonine residue (Thr1)
First covalent bond: The hydroxyl group of Thr1 (Thr1Ogamma) performs nucleophilic attack on the carbonyl carbon of the epoxyketone, forming a hemiketal intermediate
Second covalent bond: The free amino group of Thr1 (Thr1Nalpha) then opens the epoxide ring via intramolecular cyclization, generating a six-membered morpholino adduct
Irreversible inactivation: The resulting dual-covalent morpholino ring structure is thermodynamically stable and cannot be reversed under physiological conditions, permanently inactivating the beta-5 active site

This dual-covalent mechanism is unique to epoxyketone proteasome inhibitors and contrasts sharply with the single reversible tetrahedral adduct formed by bortezomib's boronic acid warhead. The requirement for both Thr1O and Thr1N ensures extraordinary selectivity: only the N-terminal threonine protease family (the proteasome) possesses both functional groups in the correct spatial arrangement, eliminating off-target inhibition of serine, cysteine, and other protease classes [3][5].

3.2 Subunit Selectivity

At clinically relevant concentrations, carfilzomib demonstrates preferential inhibition of the proteasome's three catalytic activities [5]:

| Proteasome Subunit | Catalytic Activity | Relative Sensitivity to Carfilzomib | |-------------------|-------------------|-------------------------------------| | Beta-5 (PSMB5) | Chymotrypsin-like | Primary target (IC50 approximately 5 nM) | | Beta-1 (PSMB6) | Caspase-like | Inhibited at higher concentrations | | Beta-2 (PSMB7) | Trypsin-like | Minimally affected at therapeutic doses | | Beta-5i (PSMB8/LMP7) | Immunoproteasome chymotrypsin-like | Potently inhibited |

The immunoproteasome subunits (beta-5i/LMP7, beta-1i/LMP2, beta-2i/MECL-1) are also targeted by carfilzomib, which may contribute to its activity in the bone marrow microenvironment where immunoproteasome expression is elevated [5].

3.3 Downstream Consequences of Proteasome Inhibition

Irreversible proteasome inhibition by carfilzomib leads to accumulation of polyubiquitinated proteins and disruption of multiple cellular pathways critical for myeloma cell survival [4][5][22][23]:

Unfolded protein response (UPR) activation and terminal ER stress. Multiple myeloma cells are uniquely vulnerable to proteasome inhibition due to their extraordinarily high rate of immunoglobulin synthesis. Proteasome blockade causes accumulation of misfolded proteins in the endoplasmic reticulum, triggering the UPR through PERK, IRE1alpha, and ATF6 pathways. When the UPR fails to restore proteostasis, the cells undergo apoptosis via CHOP/GADD153-mediated transcription of pro-apoptotic genes.

NF-kappaB pathway inhibition. The proteasome degrades IkappaBalpha, the endogenous inhibitor of NF-kappaB. Proteasome inhibition stabilizes IkappaBalpha, preventing nuclear translocation of NF-kappaB and suppressing transcription of anti-apoptotic genes (Bcl-2, Bcl-XL, XIAP), cytokines (IL-6, VEGF), and adhesion molecules that mediate myeloma cell survival and drug resistance.

p53 stabilization. MDM2-mediated proteasomal degradation of the tumor suppressor p53 is blocked, leading to p53 accumulation and activation of p53-dependent apoptosis and cell cycle arrest programs.

Caspase activation and apoptosis. Carfilzomib activates both intrinsic (mitochondrial, caspase-9) and extrinsic (death receptor, caspase-8) apoptotic pathways, with downstream activation of the executioner caspases-3 and -7.

Cell cycle arrest. Stabilization of p21WAF1/CIP1, p27KIP1, and cyclins leads to G2/M cell cycle arrest.

3.4 Comparison With Bortezomib: Mechanistic Differences

| Feature | Carfilzomib | Bortezomib | |---------|------------|------------| | Warhead | Alpha,beta-epoxyketone | Boronic acid | | Binding mode | Irreversible (dual covalent, morpholino adduct) | Slowly reversible (tetrahedral boronate) | | Target selectivity | Highly selective for proteasome Thr1 proteases | Cross-reacts with serine proteases (HtrA2/Omi, others) | | Proteasome recovery | Requires new proteasome synthesis (48-72 hours) | Proteasome activity recovers within 24 hours | | Peripheral neuropathy | Minimal (grade 3 or higher: 1-2%) | Significant (grade 3 or higher: 6-24%) | | Cardiovascular toxicity | Higher (cardiac events 5-8%) | Lower (cardiac events 1-3%) | | Administration | IV only | IV or subcutaneous |

4. Pharmacokinetics and Pharmacodynamics

4.1 Distribution and Protein Binding

Following intravenous administration, carfilzomib is rapidly distributed to tissues [18][19]:

Volume of distribution at steady state: 28 L
Protein binding: 97%
Maximum plasma concentrations are achieved at the end of infusion
Rapid tissue distribution and target-mediated clearance

4.2 Metabolism and Elimination

Carfilzomib undergoes rapid extrahepatic metabolism through two principal pathways [18][19]:

Peptidase cleavage: Plasma and tissue-resident peptidases cleave the tetrapeptide backbone, generating inactive peptide fragments
Epoxide hydrolysis: Microsomal epoxide hydrolase (mEH) converts the reactive epoxyketone epoxide to the inactive diol metabolite
CYP450 enzymes play no significant role in carfilzomib metabolism, minimizing drug-drug interaction potential
Systemic clearance: Exceeds hepatic blood flow, confirming predominantly extrahepatic elimination
Terminal half-life: Less than 1 hour (approximately 15-30 minutes in preclinical studies)
The extremely short half-life does not compromise efficacy because proteasome inhibition is irreversible; proteasome recovery requires de novo protein synthesis over 48-72 hours

4.3 Pharmacodynamic Effects

At the approved dose of 27 mg/m2, carfilzomib achieves greater than 80% inhibition of the chymotrypsin-like activity of the 20S proteasome in peripheral blood mononuclear cells and bone marrow, with sustained suppression for 48 hours or longer after a single dose [20][21]. The irreversible binding mechanism ensures that proteasome activity can only be restored through new proteasome synthesis, providing a pharmacodynamic advantage over bortezomib's reversible inhibition.

4.4 Special Populations

Renal impairment: No dose adjustment is required for any degree of renal impairment, including patients on dialysis -- an important practical advantage over some other myeloma therapies
Hepatic impairment: Non-CYP metabolism means hepatic impairment has minimal impact on carfilzomib pharmacokinetics; however, clinical data in severe hepatic impairment are limited

5. Clinical Trials

5.1 PX-171-003: The Pivotal Phase 2 Trial

The PX-171-003-A1 trial was the pivotal single-arm, multicenter phase 2 study that formed the basis for the July 2012 accelerated FDA approval [6]:

Population: 266 patients with relapsed and refractory multiple myeloma; median of 5 prior lines of therapy; 100% had prior bortezomib and 73% had prior lenalidomide
Regimen: Single-agent carfilzomib 20/27 mg/m2 IV twice weekly (days 1, 2, 8, 9, 15, 16 of 28-day cycle)
Overall response rate (ORR): 23.7% (primary endpoint)
Clinical benefit rate: 37.0%
Median duration of response: 7.8 months
Median overall survival: 15.6 months
Median PFS: 3.7 months

In a heavily pretreated population that had exhausted standard options, single-agent carfilzomib demonstrated clinically meaningful responses with manageable toxicity. The prior phase 2 study (PX-171-003-A0) at the lower 20 mg/m2 dose had shown an ORR of 16.7%, supporting dose escalation to 27 mg/m2 [7].

5.2 ASPIRE: KRd Versus Rd (Phase 3)

The ASPIRE trial (NCT01080391) established the carfilzomib-lenalidomide-dexamethasone (KRd) triplet as a standard of care in relapsed multiple myeloma [8][9]:

Design: Randomized, open-label, multicenter phase 3 trial
Population: 792 patients with RRMM, 1-3 prior lines of therapy
Arms: KRd (carfilzomib 20/27 mg/m2 twice weekly + lenalidomide 25 mg + dexamethasone 40 mg) vs Rd (lenalidomide + dexamethasone)
Median PFS (primary endpoint): 26.3 months (KRd) vs 17.6 months (Rd); HR 0.69, 95% CI 0.57-0.83; P = 0.0001
ORR: 87.1% (KRd) vs 66.7% (Rd)
Complete response or better: 31.8% (KRd) vs 9.3% (Rd)
Final OS analysis (2018): 48.3 months (KRd) vs 40.4 months (Rd); HR 0.79; P = 0.0045 [9]

The 7.9-month OS improvement with KRd was statistically significant and clinically meaningful. Quality-of-life analyses demonstrated significant improvements in global health status and fatigue with the addition of carfilzomib, countering concerns that triplet therapy might impair quality of life.

5.3 ENDEAVOR: Carfilzomib Versus Bortezomib Head-to-Head (Phase 3)

The ENDEAVOR trial (NCT01568866) provided the definitive head-to-head comparison of second-generation versus first-generation proteasome inhibitors [10][11]:

Design: Randomized, open-label, multicenter phase 3 trial
Population: 929 patients with RRMM, 1-3 prior lines of therapy
Arms: Kd56 (carfilzomib 20/56 mg/m2 twice weekly over 30-minute infusion + dexamethasone 20 mg) vs Vd (bortezomib 1.3 mg/m2 days 1, 4, 8, 11 + dexamethasone 20 mg)
Median PFS (primary endpoint): 18.7 months (Kd) vs 9.4 months (Vd); HR 0.53; 95% CI 0.44-0.65; P = 0.0001
ORR: 76.9% (Kd) vs 62.6% (Vd)
Interim OS analysis (2017): 47.6 months (Kd) vs 40.0 months (Vd); HR 0.79; one-sided P = 0.010 [11]
Updated OS analysis (2019): 47.8 months (Kd) vs 38.8 months (Vd); HR 0.76; 95% CI 0.63-0.92 [25]
Peripheral neuropathy (grade 2 or higher): 6% (Kd) vs 32% (Vd)
Cardiac failure (grade 3 or higher): 5% (Kd) vs 2% (Vd)

ENDEAVOR demonstrated unambiguous superiority of carfilzomib over bortezomib on all efficacy endpoints, with nearly double the PFS and a 7.6-month OS advantage. The markedly lower rate of peripheral neuropathy with carfilzomib was a major differentiating factor, though the higher incidence of cardiovascular events warranted careful patient selection and monitoring.

5.4 ARROW: Once-Weekly Versus Twice-Weekly Dosing (Phase 3)

The A.R.R.O.W. trial (NCT02412878) demonstrated the feasibility and superiority of once-weekly dosing at 70 mg/m2 [12]:

Design: Randomized, open-label, multicenter phase 3 trial
Population: 478 patients with RRMM, 2-3 prior lines (including a PI and an IMiD)
Arms: Once-weekly Kd70 (carfilzomib 20/70 mg/m2 days 1, 8, 15 over 30-minute infusion + dexamethasone 40 mg) vs twice-weekly Kd27 (carfilzomib 20/27 mg/m2 days 1, 2, 8, 9, 15, 16 over 10-minute infusion + dexamethasone 40 mg)
Median PFS (primary endpoint): 11.2 months (Kd70 once-weekly) vs 7.6 months (Kd27 twice-weekly); HR 0.69; 95% CI 0.54-0.88; P = 0.0029
ORR: 62.9% (Kd70) vs 40.8% (Kd27)
VGPR or better: 34.2% vs 13.4%
Grade 3 or higher cardiac failure: 2.6-3.3% (once-weekly) vs comparable rates (twice-weekly)

The ARROW trial led to the January 2018 supplemental FDA approval of once-weekly carfilzomib 70 mg/m2, offering patients the convenience of fewer clinic visits (3 vs 6 infusion days per cycle). Real-world prescribing data show that once-weekly 70 mg/m2 usage increased from 21% in 2016 to over 50% by 2023.

5.5 CANDOR: Adding Daratumumab to Carfilzomib (Phase 3)

The CANDOR trial (NCT03158688) evaluated the addition of the anti-CD38 monoclonal antibody daratumumab to a carfilzomib-dexamethasone backbone [13][14]:

Design: Randomized, open-label, multicenter phase 3 trial
Population: 466 patients with RRMM, 1-3 prior lines
Arms: KdD (carfilzomib + daratumumab + dexamethasone) vs Kd (carfilzomib + dexamethasone)
Median PFS (primary endpoint): 28.4 months (KdD) vs 15.2 months (Kd); HR 0.64; 95% CI 0.49-0.83; P = 0.0014
ORR: 84.3% (KdD) vs 74.7% (Kd)
MRD-negativity rate: 28% (KdD) vs 9% (Kd); OR 4.22
Final analysis (median follow-up 50 months): The favorable PFS benefit was maintained, reinforcing the risk-benefit profile of the KdD triplet [14]

CANDOR demonstrated that the addition of daratumumab to a carfilzomib backbone significantly deepened responses (including MRD negativity) and prolonged PFS, positioning KdD as a potent anti-CD38-based combination for relapsed myeloma.

5.6 FOCUS Trial

The FOCUS trial (NCT01302392) compared single-agent carfilzomib at 20/27 mg/m2 versus low-dose corticosteroids with optional cyclophosphamide in heavily pretreated patients with a median of 5 prior therapies [17]:

Population: 315 patients with advanced RRMM
Result: No significant improvement in OS (10.2 vs 10.0 months; HR 0.975)
Interpretation: The lower 27 mg/m2 dose of single-agent carfilzomib was insufficient to demonstrate survival benefit in very heavily pretreated patients, contributing to the dose escalation to 56 mg/m2 and 70 mg/m2 in subsequent trials

6. Dosing and Administration

6.1 Approved Regimens

Carfilzomib has three FDA-approved dosing configurations:

KRd (ASPIRE-based):

Carfilzomib: 20 mg/m2 IV over 10 minutes on cycle 1 days 1-2, then 27 mg/m2 on subsequent scheduled days (days 1, 2, 8, 9, 15, 16 of 28-day cycle)
Lenalidomide: 25 mg orally days 1-21
Dexamethasone: 40 mg IV or orally on days 1, 8, 15, 22
Carfilzomib administered for cycles 1-12 (days 1, 2, 8, 9, 15, 16) and cycles 13-18 (days 1, 2, 15, 16)

Kd twice-weekly (ENDEAVOR-based):

Carfilzomib: 20 mg/m2 IV over 30 minutes on cycle 1 days 1-2, then 56 mg/m2 on subsequent scheduled days (days 1, 2, 8, 9, 15, 16 of 28-day cycle)
Dexamethasone: 20 mg IV or orally on days 1, 2, 8, 9, 15, 16, 22, 23
Continue until progression or unacceptable toxicity

Kd once-weekly (ARROW-based):

Carfilzomib: 20 mg/m2 IV over 30 minutes on cycle 1 day 1, then 70 mg/m2 on days 8, 15 and all subsequent scheduled days (days 1, 8, 15 of 28-day cycle)
Dexamethasone: 40 mg IV or orally on days 1, 8, 15, 22
Continue until progression or unacceptable toxicity

6.2 Administration Considerations

Infusion duration: 10 minutes for doses at or below 27 mg/m2; 30 minutes for doses of 56 mg/m2 or 70 mg/m2 (longer infusion reduces infusion reactions)
Hydration: Administer 250-500 mL IV normal saline (or appropriate alternative) prior to each dose during cycle 1 and as needed thereafter; continue 250 mL IV fluid post-infusion
Premedication: Dexamethasone (used in all approved regimens) serves as both anticancer therapy and premedication to reduce infusion reactions
Reconstitution: Supplied as lyophilized powder (10 mg, 30 mg, or 60 mg vials); reconstitute with sterile water for injection; further dilute in 50 mL D5W for IV infusion

6.3 Dose Modifications

| Toxicity | Action | |----------|--------| | Grade 3 or 4 cardiac toxicity | Hold; restart at one dose level reduction upon recovery | | Grade 3 or 4 hematologic toxicity (ANC below 500/uL or platelets below 10,000/uL) | Hold; resume at same dose when recovered | | Grade 3 non-hematologic toxicity | Hold until resolved to grade 1 or baseline; restart at one dose level reduction | | Hepatic toxicity (bilirubin or transaminases greater than 3x ULN) | Hold until resolved; restart at one dose level reduction | | Pulmonary toxicity (dyspnea grade 3 or 4) | Hold; evaluate for drug-induced pulmonary toxicity; restart at one dose level reduction if resolved |

Dose level reductions follow the sequence: 70 to 56, 56 to 45, 45 to 36, 36 to 27, 27 to 20, 20 to 15 mg/m2. Discontinue if dose reduction below 15 mg/m2 is required.

7. Safety and Adverse Effects

7.1 Cardiovascular Toxicity

Cardiovascular adverse events represent the most clinically significant toxicity distinguishing carfilzomib from bortezomib [15][16][24]:

Incidence: A systematic review and meta-analysis of 24 studies including 2,594 patients found all-grade cardiovascular adverse events (CVAE) in 18.1% and high-grade (grade 3 or higher) CVAE in 8.2% [15].

Specific cardiovascular events:

Cardiac failure: 4-8% (grade 3 or higher: 3-5%); the strongest pharmacovigilance signal
Hypertension: 12-25% (grade 3 or higher: 4-9%)
Ischemic heart disease: 1-4%
Arrhythmias: 2-5%
Pulmonary hypertension: Rare but serious; stronger signal than with bortezomib
Embolic and thrombotic events: Reported in up to 3% of patients

Proposed mechanisms:

Direct oxidative stress on cardiac myocytes from proteasome inhibition impairing protein quality control
Endothelial dysfunction secondary to proteasome inhibition in vascular endothelium, leading to increased vascular tone and hypertension
Impaired cardiac proteasomal degradation of misfolded sarcomeric proteins
Increased coronary vascular reactivity

Risk management:

Baseline cardiovascular assessment with ECG and echocardiography recommended before treatment initiation
Close monitoring for signs and symptoms of cardiac failure, ischemia, and arrhythmias throughout treatment
Adequate hydration and blood pressure control
Consider cardiology consultation for patients with pre-existing cardiac disease

7.2 Infusion Reactions

Infusion-related reactions occur in approximately 3-10% of patients and are typically most common during the first cycle [23]:

Symptoms include fever, chills, rigors, dyspnea, chest tightness, arthralgia, facial flushing, and vomiting
Pre-medication with dexamethasone mitigates the incidence and severity
Extending infusion duration from 10 to 30 minutes (mandatory for doses above 27 mg/m2) significantly reduces infusion reactions
Most reactions are grade 1-2 and manageable with standard supportive care

7.3 Hematologic Toxicity

Thrombocytopenia: 29-45% (grade 3 or higher: 10-30%); typically transient and cyclical
Anemia: 35-50% (grade 3 or higher: 10-20%)
Neutropenia: 25-40% (grade 3 or higher: 8-15%)
Lymphopenia: 15-30%
Complete blood count monitoring required prior to each cycle

7.4 Other Adverse Effects

Renal:

Acute renal failure: 3-8% (grade 3 or higher: 2-4%)
Tumor lysis syndrome: Rare but reported, particularly during initial dosing

Pulmonary:

Dyspnea: 25-35%
Pulmonary arterial hypertension: Rare
Interstitial lung disease: Rare

Gastrointestinal:

Nausea: 25-45%
Diarrhea: 25-40%
Vomiting: 10-20%

Hepatic:

Transaminase elevations: 10-15% (grade 3 or higher: 1-3%)
Hepatic failure: Rare

Neurologic:

Peripheral neuropathy (all grades): 6-14%
Peripheral neuropathy (grade 3 or higher): 1-2% -- markedly lower than bortezomib (6-24%)
Headache: 15-28%

Constitutional:

Fatigue: 40-60%
Pyrexia: 25-35%

7.5 Embryo-Fetal Toxicity

Carfilzomib can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for at least 30 days after the last dose. Males should use effective contraception during treatment and for 90 days after the last dose.

8. Development History and Regulatory Timeline

| Date | Event | |------|-------| | 1992 | Epoxomicin isolated from Actinomyces strain Q996-17 by Hanada et al. [1] | | 1999 | Crews laboratory identifies epoxomicin as a selective proteasome inhibitor [2] | | 2000 | Crystal structure reveals dual-covalent morpholino adduct mechanism [3] | | 2002 | Proteolix founded; begins developing clinical candidates from YU-101 | | 2005 | Carfilzomib (PR-171) enters phase 1 clinical trials | | 2007 | Preclinical antitumor activity published; Demo et al. and Kuhn et al. [4][5] | | 2009 | Onyx Pharmaceuticals acquires Proteolix for approximately $276 million | | January 2011 | FDA grants fast-track designation for carfilzomib | | July 20, 2012 | FDA accelerated approval for RRMM (based on PX-171-003-A1) [6] | | October 2013 | Amgen acquires Onyx Pharmaceuticals for $10.4 billion | | January 2015 | ASPIRE results published in NEJM; Stewart et al. [8] | | July 2015 | FDA supplemental approval for KRd combination (ASPIRE) | | January 2016 | FDA supplemental approval for Kd56 combination (ENDEAVOR) [10] | | 2017 | ENDEAVOR interim OS confirms carfilzomib superiority over bortezomib [11] | | January 2018 | FDA supplemental approval for once-weekly Kd70 (ARROW) [12] | | 2020 | CANDOR results published: KdD vs Kd [13] | | 2023 | CANDOR final analysis confirms durable PFS benefit with KdD [14] | | 2025 | ADVANCE trial evaluates DKRd (daratumumab + KRd) vs KRd in newly diagnosed MM, with MRD negativity as primary endpoint |

9. Pharmacokinetics: Detailed Profile

9.1 Comprehensive PK Parameters

Carfilzomib has a distinctive pharmacokinetic profile characterized by extremely rapid systemic clearance but prolonged pharmacodynamic effects due to irreversible target binding [18][19][20].

| PK Parameter | Value | Clinical Significance | |---|---|---| | Terminal half-life | Less than 1 hour (~15-30 min) | Shortest of all proteasome inhibitors; does not limit efficacy due to irreversible binding | | Protein binding | 97% | Primarily to albumin and alpha-1-acid glycoprotein | | Volume of distribution (Vss) | 28 L | Rapid tissue distribution | | Systemic clearance | 263 L/hr (exceeds hepatic blood flow) | Confirms predominantly extrahepatic metabolism | | Cmax (27 mg/m2, 10-min infusion) | ~2,300 ng/mL | Peak at end of infusion | | Cmax (56 mg/m2, 30-min infusion) | ~4,200 ng/mL | Dose-proportional increase | | AUC (27 mg/m2) | ~379 nghr/mL | Low systemic exposure despite high target engagement | | AUC (56 mg/m2) | ~948 nghr/mL | Approximately dose-proportional | | Metabolism | Peptidase cleavage + epoxide hydrolysis (non-CYP450) | No significant drug-drug interactions | | Renal excretion | Less than 1% unchanged drug | No renal dose adjustment needed | | Hepatic metabolism | CYP450-independent | No hepatic dose adjustment for mild-moderate impairment |

9.2 Proteasome Inhibitor PK Comparison

| PK Feature | Carfilzomib | Bortezomib | Ixazomib | |---|---|---|---| | Route | IV only | IV or SC | Oral | | Half-life | Less than 1 hour | ~9-15 hours | ~9.5 days | | Protein binding | 97% | 83% | 99% | | Metabolism | Non-CYP (peptidase, epoxide hydrolase) | CYP3A4, CYP2C19, CYP1A2 | CYP3A4, CYP1A2 | | Drug interactions | Minimal (non-CYP) | CYP3A4 inhibitors/inducers | CYP3A4 inhibitors/inducers | | Renal adjustment | None required | None required | None required | | PD duration | 48-72 hours (requires new proteasome synthesis) | ~24 hours (reversible binding) | 24-48 hours | | PK/PD disconnect | Extreme -- drug cleared in less than 1 hour, effect lasts days | Moderate | Moderate |

The extreme pharmacokinetic-pharmacodynamic disconnect of carfilzomib is its most distinctive feature: while the drug itself is cleared from the circulation in under an hour, the irreversible nature of its covalent bond with the proteasome beta-5 subunit ensures that proteasome function can only be restored through de novo protein synthesis, a process requiring 48-72 hours. This means that systemic drug exposure is minimized (reducing off-target toxicity to non-proteasome targets) while target engagement is maximized and sustained [5][19].

9.3 Infusion Rate and PK/Safety Relationship

The transition from 10-minute to 30-minute infusion for higher doses was driven by safety rather than efficacy considerations [20]:

At 20/27 mg/m2: 10-minute infusion produces acceptable Cmax
At 56 mg/m2: 30-minute infusion reduces peak Cmax by approximately 50% compared to a hypothetical 10-minute infusion, substantially reducing infusion-related reactions
At 70 mg/m2: 30-minute infusion required; the lower Cmax despite higher total dose reduces infusion reactions while maintaining equivalent proteasome inhibition
Extending infusion beyond 30 minutes does not further improve the therapeutic window

10. Dose-Response Relationship and Proteasome Inhibition

10.1 Proteasome Inhibition by Dose Level

The dose-response relationship for carfilzomib has been extensively characterized through pharmacodynamic studies measuring proteasome activity in whole blood, peripheral blood mononuclear cells, and bone marrow [5][20][21]:

| Dose (mg/m2) | Beta-5 CT-L Inhibition (PBMCs) | Duration of Greater Than 80% Inhibition | Clinical Context | |---|---|---|---| | 15 | ~70% | Less than 24 hours | Below therapeutic threshold | | 20 | ~80% | ~24 hours | Cycle 1 starting dose (all regimens) | | 27 | Greater than 80% | 48+ hours | KRd maintenance dose (ASPIRE) | | 36 | Greater than 85% | 48-72 hours | Dose reduction level | | 45 | ~90% | 48-72 hours | Dose reduction level | | 56 | Greater than 90% | 72+ hours | Kd twice-weekly dose (ENDEAVOR) | | 70 | Greater than 90% | 72+ hours | Kd once-weekly dose (ARROW) |

10.2 Clinical Dose-Response Across Trials

The clinical development of carfilzomib demonstrates a clear dose-response relationship for efficacy:

| Trial/Dose | ORR | Median PFS | Key Insight | |---|---|---|---| | PX-171-003-A0 (20 mg/m2) | 16.7% | ~2.9 months | Subtherapeutic in heavily pretreated patients | | PX-171-003-A1 (20/27 mg/m2) | 23.7% | 3.7 months | Adequate for accelerated approval | | FOCUS (20/27 mg/m2) | 19.1% | 3.6 months | No OS benefit over corticosteroids at this dose | | ASPIRE-KRd (20/27 mg/m2) | 87.1% | 26.3 months | Synergy with Rd compensates for lower dose | | ENDEAVOR-Kd (20/56 mg/m2) | 76.9% | 18.7 months | Dose escalation to 56 mg/m2 drove superiority over bortezomib | | ARROW-Kd (20/70 mg/m2 weekly) | 62.9% | 11.2 months | Higher single-dose intensity overcomes reduced frequency | | ARROW-Kd (20/27 mg/m2 twice-weekly) | 40.8% | 7.6 months | Reference arm confirms lower-dose inferiority |

The FOCUS trial failure (no OS benefit at 27 mg/m2 monotherapy) was a pivotal learning point: it demonstrated that the 27 mg/m2 dose was insufficient for monotherapy in heavily pretreated patients, directly motivating the dose escalation to 56 mg/m2 (ENDEAVOR) and 70 mg/m2 (ARROW) [17]. The ARROW trial provided the most definitive intra-carfilzomib dose-response data: once-weekly 70 mg/m2 was significantly superior to twice-weekly 27 mg/m2 (PFS 11.2 vs 7.6 months; HR 0.69) despite fewer infusion days, establishing that dose intensity per administration matters more than dosing frequency [12].

11. Comparative Effectiveness: Carfilzomib vs Bortezomib (ENDEAVOR and Beyond)

11.1 ENDEAVOR Head-to-Head Data

The ENDEAVOR trial provides the definitive comparative effectiveness data for carfilzomib versus bortezomib [10][11][25]:

| Endpoint | Carfilzomib 56 mg/m2 (Kd) | Bortezomib 1.3 mg/m2 (Vd) | Hazard Ratio / Difference | |---|---|---|---| | Median PFS | 18.7 months | 9.4 months | HR 0.53 (p less than 0.0001) | | ORR | 76.9% | 62.6% | Difference +14.3% | | CR or better | 12.5% | 6.2% | Difference +6.3% | | Median OS (final) | 47.8 months | 38.8 months | HR 0.76 (p = 0.010) | | Peripheral neuropathy (grade 2+) | 6% | 32% | 5.3-fold reduction | | Cardiac failure (grade 3+) | 5% | 2% | 2.5-fold increase | | Thrombocytopenia (grade 3+) | 18% | 9% | 2-fold increase | | Hypertension (grade 3+) | 9% | 3% | 3-fold increase | | Median time on treatment | 11.8 months | 8.0 months | 3.8 months longer |

11.2 Subgroup-Specific Superiority

ENDEAVOR subgroup analyses demonstrated consistent carfilzomib superiority across pre-specified subgroups [11][25]:

Prior bortezomib exposure: PFS HR 0.56 (carfilzomib superior despite prior PI exposure)
High-risk cytogenetics [del(17p), t(4;14), t(14;16)]: PFS HR 0.64 (benefit maintained in high-risk disease)
ISS stage III: PFS HR 0.51 (greatest relative benefit in advanced disease)
Age 65-74: PFS HR 0.49 (maintained benefit in elderly patients)
1 prior line: PFS HR 0.44 (earlier use may provide greater benefit)
2-3 prior lines: PFS HR 0.58 (sustained benefit with increasing prior therapy)

11.3 Risk-Benefit Contextualization

The choice between carfilzomib and bortezomib requires individualized risk-benefit assessment:

Favor carfilzomib (Kd56 or Kd70) when:

Maximizing PFS/OS is the primary goal
Pre-existing peripheral neuropathy (bortezomib-induced or diabetic)
Bortezomib-refractory disease
Patient can attend IV infusion visits
No significant cardiovascular comorbidities (NYHA class I-II or no cardiac history)

Favor bortezomib when:

Significant cardiovascular disease (CHF, recent MI, uncontrolled hypertension)
SC administration preferred (home administration possible)
First-line treatment (bortezomib + lenalidomide + dexamethasone [VRd] is standard frontline)
Cost considerations (bortezomib is generic)

12. Enhanced Safety: Cardiovascular Risk Management

12.1 Cardiovascular Adverse Event Detailed Profile

The cardiovascular toxicity of carfilzomib has been characterized across 24 studies in a systematic meta-analysis encompassing 2,594 patients [15]:

| Cardiovascular Event | All Grades | Grade 3 or Higher | Onset Pattern | |---|---|---|---| | Heart failure | 4-8% | 3-5% | Most common in cycles 1-3 | | Hypertension | 12-25% | 4-9% | Can occur at any time; may be cumulative | | Ischemic heart disease | 1-4% | 1-3% | No clear temporal pattern | | Arrhythmias (any) | 2-5% | 1-2% | Variable | | Pulmonary hypertension | 1-2% | Less than 1% | Delayed onset | | Venous thromboembolism | 2-3% | 1-2% | Throughout treatment | | Sudden cardiac death | Less than 1% | N/A | Unpredictable | | Composite CVAE | 18.1% | 8.2% | Highest risk in first 3 cycles |

12.2 SEER-Medicare Real-World Cardiovascular Data

Real-world cardiovascular safety data from SEER-Medicare analysis of 1,244 patients confirmed and extended the clinical trial findings [24]:

All-grade cardiovascular events: 23.7% (higher than clinical trials, reflecting older, comorbid population)
Heart failure: 13.1% (higher than trials)
Arrhythmias: 10.5%
Ischemic events: 5.2%
Patients with pre-existing cardiovascular disease had 2.1-fold higher risk of carfilzomib-associated cardiac events

12.3 Recommended Cardiovascular Monitoring Protocol

Baseline (before cycle 1):

ECG (12-lead)
Echocardiogram with LVEF assessment
BNP or NT-proBNP
Blood pressure measurement
Review cardiovascular risk factors and medications

During treatment:

Blood pressure monitoring at each infusion visit
ECG if new symptoms develop
Echocardiogram if clinical suspicion of heart failure (new dyspnea, edema, weight gain)
Repeat BNP/NT-proBNP if baseline was elevated or symptoms develop
Cardiology consultation for patients developing grade 2+ cardiovascular events

Dose modification for cardiovascular events:

Grade 3 hypertension: Hold until controlled; restart at same dose with antihypertensive optimization
Grade 3 cardiac failure: Hold until recovery; restart at one dose level reduction
Grade 4 cardiac event: Discontinue permanently
Recurrent grade 3 cardiac event: Consider permanent discontinuation

12.4 Proposed Cardioprotective Strategies

Evidence-based and consensus-recommended strategies to mitigate cardiovascular risk include [15][16]:

Aggressive hydration (250-500 mL IV saline pre- and post-infusion)
Blood pressure optimization before each cycle (target less than 140/90 mmHg)
Use of 30-minute infusion for doses above 27 mg/m2
Cardiology co-management for patients with NYHA class II heart failure, prior MI, or LVEF less than 50%
Consider dexrazoxane in patients with high cumulative anthracycline exposure
Avoid concomitant cardiotoxic agents when possible
Early detection and treatment of new-onset hypertension with ACE inhibitors or ARBs

13. Comparison With Other Proteasome Inhibitors

9.1 Approved Proteasome Inhibitors for Multiple Myeloma

Three proteasome inhibitors are FDA-approved for multiple myeloma: bortezomib (2003), carfilzomib (2012), and ixazomib (2015).

| Property | Carfilzomib | Bortezomib | Ixazomib | |---------|------------|------------|----------| | Chemical class | Epoxyketone tetrapeptide | Boronic acid dipeptide | Boronic acid (citrate ester prodrug) | | Binding mode | Irreversible | Slowly reversible | Reversible | | Selectivity | Beta-5 highly selective | Beta-5 + off-target proteases | Beta-5 selective | | Administration | IV only | IV or SC | Oral | | Schedule | Weekly or twice-weekly | Weekly or twice-weekly | Once-weekly (days 1, 8, 15) | | Peripheral neuropathy | Low (1-2% grade 3 or higher) | High (6-24% grade 3 or higher) | Moderate (2-5% grade 3 or higher) | | Cardiac toxicity | Higher (5-8% grade 3 or higher) | Lower (1-3%) | Low | | Proteasome recovery | 48-72 hours (requires de novo synthesis) | 24 hours | 24-48 hours |

9.2 ENDEAVOR: Definitive Head-to-Head Evidence

The ENDEAVOR trial remains the only completed randomized phase 3 study directly comparing two proteasome inhibitors in multiple myeloma [10][11][25]. Key conclusions:

Carfilzomib at 56 mg/m2 is statistically and clinically superior to bortezomib on PFS (HR 0.53), ORR, and OS (HR 0.76)
The PFS benefit was consistent across pre-specified subgroups including age, ISS stage, prior bortezomib exposure, and cytogenetic risk
Peripheral neuropathy was dramatically reduced with carfilzomib (6% vs 32% grade 2 or higher), representing a major quality-of-life advantage
Cardiovascular toxicity was higher with carfilzomib, requiring careful risk-benefit assessment
The OS benefit of approximately 9 months establishes carfilzomib as the preferred proteasome inhibitor for patients without significant cardiovascular comorbidity

14. Resistance Mechanisms

Resistance to carfilzomib can develop through several mechanisms [22][23]:

PSMB5 mutations: Point mutations in the beta-5 subunit gene (particularly at positions A49, C52, and A20) alter the substrate binding pocket geometry, reducing carfilzomib binding affinity
Proteasome subunit overexpression: Upregulation of beta-5 (PSMB5) expression increases the total proteasome pool, requiring higher drug concentrations for effective inhibition
P-glycoprotein (ABCB1) efflux: Overexpression of P-gp efflux pumps can reduce intracellular carfilzomib accumulation, though this mechanism appears less significant than for bortezomib
Altered UPR signaling: Adaptive changes in the unfolded protein response (e.g., IRE1alpha/XBP1 pathway modulation) can enable cells to tolerate proteasome inhibition
NF-kappaB pathway mutations: Constitutive NF-kappaB activation through upstream mutations bypasses the need for proteasomal IkappaBalpha degradation

15. Summary

Carfilzomib represents a paradigm of mechanism-driven drug development in oncology -- from the discovery of a natural product proteasome inhibitor (epoxomicin) through elucidation of its unprecedented dual-covalent mechanism, to rational chemical optimization yielding a clinically superior second-generation agent. Its irreversible epoxyketone warhead provides more complete and sustained proteasome inhibition than the reversible boronate of bortezomib, translating into superior PFS and OS in the head-to-head ENDEAVOR trial (median OS 47.6 vs 40.0 months) and dramatically lower rates of peripheral neuropathy [10][11].

The clinical development program of carfilzomib has been defined by five landmark trials. The PX-171-003 phase 2 trial secured accelerated approval in heavily pretreated patients [6]. ASPIRE established KRd as a standard triplet, demonstrating an 8.7-month PFS advantage and 7.9-month OS advantage over Rd [8][9]. ENDEAVOR proved carfilzomib's superiority over bortezomib in direct comparison [10][11]. ARROW enabled once-weekly dosing at 70 mg/m2, improving patient convenience without sacrificing efficacy [12]. CANDOR showed that adding daratumumab to a carfilzomib backbone further extended PFS to 28.4 months with deep MRD-negative responses [13][14].

The principal limitation of carfilzomib is its cardiovascular toxicity profile, with grade 3 or higher cardiac events occurring in 5-8% of patients across clinical trials [15][16]. This necessitates baseline cardiac assessment, careful patient selection, adequate hydration, and vigilant monitoring throughout treatment. Ongoing research continues to refine optimal dosing strategies, explore novel combinations, and identify biomarkers for both response prediction and cardiac risk stratification.

As the proteasome inhibitor class matures within the multiple myeloma treatment landscape, carfilzomib's irreversible mechanism, proven survival benefits, and favorable neurologic safety profile ensure its continued role as a backbone agent in combination regimens for relapsed and refractory disease. The 2025 ADVANCE trial exploring daratumumab plus KRd (DKRd) in newly diagnosed MM represents the latest effort to integrate carfilzomib into frontline quadruplet regimens, building on the success of anti-CD38-based combinations. Additionally, a 2025 comprehensive review of carfilzomib-associated cardiac toxicity has further characterized the cardiovascular risk profile, with cardiovascular adverse events reported in 7-27% of carfilzomib-treated patients versus 0.6-4.1% for bortezomib, reinforcing the need for proactive cardiac monitoring.

[1] Hanada M, Sugawara K, Kaneta K, et al. (1992). Epoxomicin, a new antitumor agent of microbial origin. Journal of Antibiotics. DOI PubMed
[2] Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Bhatt R, Heppner DG, Borrow J, Crews CM. (1999). Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the National Academy of Sciences. DOI PubMed
[3] Groll M, Kim KB, Kaber N, Huber R, Crews CM. (2000). Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of alpha,beta-epoxyketone proteasome inhibitors. Journal of the American Chemical Society. DOI PubMed
[4] Demo SD, Kirk CJ, Aujay MA, et al. (2007). Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research. DOI PubMed
[5] Kuhn DJ, Chen Q, Voorhees PM, et al. (2007). Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. DOI PubMed
[6] Siegel DS, Martin T, Wang M, et al. (2012). A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. DOI PubMed
[7] Vij R, Wang M, Kaufman JL, et al. (2012). An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. DOI PubMed
[8] Stewart AK, Rajkumar SV, Dimopoulos MA, et al. (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine. DOI PubMed
[9] Siegel DS, Dimopoulos MA, Ludwig H, et al. (2018). Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology. DOI PubMed
[10] Dimopoulos MA, Moreau P, Palumbo A, et al. (2016). Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology. DOI PubMed
[11] Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. (2017). Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncology. DOI PubMed
[12] Moreau P, Mateos MV, Berber JJ, et al. (2018). Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncology. DOI PubMed
[13] Dimopoulos M, Quach H, Mateos MV, et al. (2020). Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. DOI PubMed
[14] Dimopoulos M, Quach H, Mateos MV, et al. (2023). Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Advances. DOI PubMed
[15] Waxman AJ, Clasen S, Hwang WT, et al. (2018). Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncology. DOI PubMed
[16] Cornell RF, Ky B, Weiss BM, et al. (2019). Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. Journal of Clinical Oncology. DOI PubMed
[17] Hájek R, Masszi T, Petrucci MT, et al. (2017). A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. DOI PubMed
[18] Yang J, Wang Z, Fang Y, et al. (2011). Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metabolism and Disposition. DOI PubMed
[19] Wang Z, Yang J, Kirk C, et al. (2013). Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metabolism and Disposition. DOI PubMed
[20] Papadopoulos KP, Siegel DS, Vesole DH, et al. (2015). Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. Journal of Clinical Oncology. DOI PubMed
[21] Berenson JR, Cartmell A, Bessudo A, et al. (2016). CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. DOI PubMed
[22] Musto P, La Rocca F. (2013). Carfilzomib for multiple myeloma. Expert Opinion on Pharmacotherapy. DOI PubMed
[23] Chowdhury S, Bhatt R, Bhattacharyya R, et al. (2021). Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Frontiers in Oncology. DOI PubMed
[24] Bishnoi R, Xie Z, Shah C, et al. (2021). Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. Cancer Medicine. DOI PubMed
[25] Dimopoulos MA, Dytfeld D, Grosicki S, et al. (2019). Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clinical Lymphoma Myeloma and Leukemia. DOI PubMed

Carfilzomib (Kyprolis, PR-171)